New agent targets EGFR resistance in NSCLC

A new agent targeting tumors that develop resistance to EGFR tyrosine kinase inhibitors proved to be “highly active” in a phase I clinical trial i... More »

Field of Interest: Oncology
Type: News Item

Rociletinib active against resistant NSCLC

Rociletinib, a third-generation EGFR tyrosine kinase inhibitor that targets mutations causing treatment resistance, showed sustained activity against ... More »

Field of Interest: Oncology
Type: News Item

PC providers have knowledge gaps in lung cancer screening

CHICAGO – Nearly one-fourth of primary care providers were unaware of current lung cancer screening guidelines in a survey of 212 PC providers in North Carolina, a state with one of the nation’s...

Field of Interest: Oncology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.